Amryt Pharma (Amryt Pharma) Net Change in Cash : $-39.8 Mil (TTM As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Amryt Pharma's Net Change in Cash for the three months ended in Sep. 2022 was $-7.3 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 was $-39.8 Mil.

Amryt Pharma Net Change in Cash Historical Data

The historical data trend for Amryt Pharma's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Net Change in Cash Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Change in Cash

Get a 7-Day Free Trial

14.69

-13.19

56.00

51.57

-5.77

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Net Change in Cash	Get a 7-Day Free Trial															-19.77	-10.15	-10.81	-11.49	-7.33

Amryt Pharma Net Change in Cash Calculation

Amryt Pharma's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	15.54	+	106.402	+	-125.426	+	-2.282
	=	-5.8

Amryt Pharma's Net Change in Cash for the quarter that ended in Sep. 2022

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 14.337 + -16.431 + -5.057 + -0.182

= -7.3

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amryt Pharma Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Amryt Pharma's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Net Change in Cash

Comparable Companies

TARO COLL AVDL DCPH HROW ANIP PAHC DVAX PROC EOLS ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 SZSE:000538 TSE:4507 SHSE:600085 SHSE:600196

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).

Amryt Pharma (Amryt Pharma) Headlines

From GuruFocus

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa� (oral octreotide) for the Treatment of Carcinoid Syndrome
By PurpleRose PurpleRose • 07-14-2022

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Amryt Pharma Plc - AMYT
By PRNewswire PRNewswire • 01-10-2023

European Commission approves Mycapssa� for the treatment of Acromegaly
By Value_Insider Value_Insider • 12-05-2022

Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
By sperokesalga sperokesalga • 03-22-2023

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez�) NDA
By PurpleRose PurpleRose • 07-14-2022

Amryt Supports Global EB Awareness Week 2022
By Value_Insider Value_Insider • 10-24-2022

AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT
By Business Wire Business Wire • 02-24-2023

AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023
By sperokesalga sperokesalga • 02-16-2023

AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
By Business Wire Business Wire • 02-27-2023

COMP adopts positive opinion on Orphan Disease Designation for Mycapssa� for the treatment of Acromegaly
By Value_Insider Value_Insider • 10-18-2022